The impact of farnesol in combination with fluconazole on Candida albicans biofilm: regulation of ERG20, ERG9, and ERG11 genes
- 107 Downloads
Farnesol (FAR) has already demonstrated an inhibitory effect on Candida albicans biofilm. The aim of this work was to determine the effectiveness of externally added FAR in combination with fluconazole (FLC) on Candida albicans biofilm and on regulation of the ergosterol genes ERG20, ERG9, and ERG11. The effectiveness of compounds was determined by MTT assay and evaluated by the minimal inhibitory concentrations reducing a sessile biofilm to 50% activity (0.5 μg/mL and 200 μmol/L for FLC and FAR, respectively). These concentrations as well as 30 and 100 μmol/L FAR were selected for a study of the effectiveness of the FAR/FLC combination. The reduction in biofilm robustness mainly caused by the presence of 200 μmol/L FAR—alone or in combination with FLC—was accompanied by a significant inhibition of the yeast-to-hyphae transition that was observed by light microscopy and CLSM. Results from qRT-PCR indicated that while 30 μmol/L FAR only slightly regulated the expression of all 3 genes in the 48-h biofilm, the presence of 200 μmol/L FAR downregulated all the tested genes. However, the addition of 0.5 μg/mL of FLC to the samples with 200 μmol/L FAR restored the downregulation of the ERG20 and ERG11 genes to the control level. Moreover, the gene ERG9 was slightly upregulated. In summary, FAR acted via multiple effects on the C. albicans biofilm, but only a higher concentration of FAR proved to be effective.
We wish to thank to MSc. Marek Korenčák and Dr. Imrich Hikkel, PhD. for the design of primers.
SD performed majority of experiments and evaluated data, LČ participated in preparation of figures, evaluation of data, and revision of manuscript, HB designed manuscript, participated in evaluation of data, and writing manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Borecká-Melkusová S, Moran GP, Sullivan DJ, Kucháriková S, Chorvát DJ, Bujdákova H (2009) The expression of genes involved in the ergosterol biosynthesis pathway in Candida albicans and Candida dubliniensis biofilms exposed to fluconazole. Mycoses 52(2):118–128. https://doi.org/10.1111/j.1439-0507.2008.01550.x CrossRefPubMedGoogle Scholar
- Bujdáková H, Kuchta T, Sidóová E, Gvozdjaková A (1993) Anti-Candida activity of four antifungal benzothiazoles. FEMS Microbiol Lett 112(3):329–333. https://doi.org/10.1111/j.1574-6968.1993.tb06471.x CrossRefPubMedGoogle Scholar
- Daum G, Lees ND, Bard M, Dickson R (1998) Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast 14(16):1471–1510. https://doi.org/10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y CrossRefPubMedGoogle Scholar
- Guedouari H, Gergondey R, Bourdais A, Vanparis O, Bulteau AL, Camadro JM, Auchère F (2014) Changes in glutathione-dependent redox status and mitochondrial energetic strategies are part of the adaptive response during the filamentation process in Candida albicans. Biochim Biophys Acta 1842(9):1855–1869. https://doi.org/10.1016/j.bbadis.2014.07.006 CrossRefPubMedGoogle Scholar
- Hornby JM, Nickerson KW (2004) Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob Agents Chemother 48(6):2305–2307. https://doi.org/10.1128/AAC.48.6.2305-2307.2004
- Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P, Nickerson KW (2001) Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 67(7):2982–2992. https://doi.org/10.1128/AEM.67.7.2982-2992.2001 CrossRefPubMedPubMedCentralGoogle Scholar
- Katragkou A, McCarthy M, Alexander EL, Antachopoulos C, Meletiadis J, Jabra-Rizk MA, Petraitis V, Roilides E, Walsh TJ (2015) In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. J Antimicrob Chemother 70(2):470–478. https://doi.org/10.1093/jac/dku374 CrossRefPubMedGoogle Scholar
- Mosel DD, Dumitru R, Hornby JM, Atkin AL, Nickerson KW (2005) Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum. Appl Environ Microbiol 71(8):4938–4940. https://doi.org/10.1128/AEM.71.8.4938-4940.2005 CrossRefPubMedPubMedCentralGoogle Scholar
- Parks LW, Casey WM (1995) Physiological implications of sterol biosynthesis in yeast. Annu Rev Microbiol 49(1):95–116. https://doi.org/10.1146/annurev.mi.49.100195.000523 CrossRefPubMedGoogle Scholar
- Rajendran R, Sherry L, Nile CJ, Sherriff A, Johnson EM, Hanson MF, Williams C, Munro CA, Jones BJ, Ramage G (2016) Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland, 2012-2013. Clin Microbiol Infect 22(1):87–93. https://doi.org/10.1016/j.cmi.2015.09.018 CrossRefPubMedPubMedCentralGoogle Scholar
- Sanglard D, Ischer F, Koymans L, Bille J (1998) Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42(2):241–253CrossRefPubMedPubMedCentralGoogle Scholar
- Sharma M, Prasad R (2011) The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob Agents Chemother 55(10):4834–4843. https://doi.org/10.1128/AAC.00344-11 CrossRefPubMedPubMedCentralGoogle Scholar
- Tashiro M, Kimura S, Tateda K, Saga T, Ohno A, Ishii Y, Izumikawa K, Tashiro T, Kohno S, Yamaguchi K (2012) Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis. Med Mycol 50(4):353–360. https://doi.org/10.3109/13693786.2011.610037 CrossRefPubMedGoogle Scholar
- Zhu J, Krom BP, Sanglard D, Intapa C, Dawson CC, Peters BM, Shirtliff ME, Jabra-Rizk MA (2011) Farnesol-induced apoptosis in Candida albicans is mediated by Cdr1-p extrusion and depletion of intracellular glutathione. PLoS One 6(12):e28830. https://doi.org/10.1371/journal.pone.0028830 CrossRefPubMedPubMedCentralGoogle Scholar